Second, it defines a biomarker-driven stratification schema: EMT-high/NCSC-high tumors, including melanoma, neuroblastoma, small-cell lung cancer, and subsets of pancreatic and triple-negative breast cancers, are predicted to be most RAX-dependent and thus therapeutically targetable. This evidence concerns the gene RAX and melanoma.